Why Dendreon's begging bowl repels investors
This article was originally published in Scrip
Dendreon's market capitalization hit a 10-year low on 12 August 2014. As if primed to expect bad news in August (Dendreon's stock price and valuation have fallen by more than 30% in each of the last four Augusts), the reaction from the market was almost instantaneous: Dendreon's share price dropped from $2.11 at the close on 11 August to $1.54 at the start of 12 August closing at $1.38, a 35% loss on the day wiping 33% or $115m of the company's increasingly meager valuation.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.